About Siliphos
Siliphos (silybin phytosome, IdB 1016) is a patented complex of silybin — the most potent flavolignan in milk thistle (~50–70% of silymarin) — bound to phosphatidylcholine. Standard silymarin has ~2% oral bioavailability; the phytosome achieves ~10× higher plasma silybin levels in human pharmacokinetic studies (peak 1,004 vs 139 ng/mL). Phosphatidylcholine is itself hepatoprotective, making the combination synergistic for liver health. A Phase III double-blind trial (n=179, 12 months) showed significant improvements in liver enzymes, insulin resistance (HOMA-IR), and liver histology in NAFLD patients. A pediatric trial (n=50) showed significant AST reductions in chemotherapy-induced hepatotoxicity. Silybin does not show significant drug interactions at standard doses. Safety margin is wide — no significant side effects below 10 g/day. Minor GI discomfort is rare (<6% of patients). No established RDA/UL.
What Siliphos supports
- Supports liver health with ~10× absorption over standard milk thistle
- Clinically shown to improve liver enzymes and histology in NAFLD
- Phase III trial demonstrated improvements in insulin resistance
- Phosphatidylcholine carrier is itself hepatoprotective and synergistic
How much Siliphos to take
The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.
Effective
360–1080
mg
Clinical studies use 120–360 mg/day of silybin content from phytosome form. Siliphos is ~30% silybin by weight, so 360–1,080 mg of the complex delivers the clinical range. Most supplements provide 180 mg Siliphos per capsule at 2–3 capsules/day. The landmark Phase III NAFLD trial used Realsil (silybin 188 mg/day as phytosome).
Clinical evidence
Moderate clinical evidence. Phase III trial (179 patients, 12 months) showed significant liver improvements in NAFLD
Examine.com